Fraud's not that big of a deal: the Valeant story, according to Bill Ackman

FierceBiotech Radio

Nov 5, 201529:46Science & Medicine

Fierce editors discuss the latest turns in the Valeant Pharmaceuticals saga, the seeming inevitability of a Pfizer-Allergan merger, and Shire's up-and-down efforts to buy stuff it wants.

Related Episodes

Continue listening to more episodes from FierceBiotech Radio.

Pricing drugs, selling hype and how we got here in the first place

May 15, 2018 - 15:46

FierceBiotech chats with a pair of lawyers about how drug pricing is unique in the U.S. and how the bioph...

The FierceMadness drug name showdown and how do drugs get their zany names anyway?

Mar 13, 2018 - 21:26

Fierce editors discuss the 2018 FierceMadness drug name tournament, its origins, and our favorites headin...

Back from the dead: FierceBiotech Radio at the Battle of the Biotech Bands

Oct 31, 2017 - 09:46

FierceBiotech Radio rose from the grave for this special Halloween episode where we sat down with some of...

GSK's CEO shakeup, Lilly's Alzheimer's uncertainty, and Valeant's latest disaster

Mar 18, 2016 - 28:41

Fierce editors discuss the pending retirement of GlaxoSmithKline CEO Andrew Witty, Eli Lilly's bold decis...

The FDA's new boss, Sanofi's latest shortcut, and a little 'financial innovation'

Feb 26, 2016 - 41:26

Fierce editors discuss the confirmation of Robert Califf as the next FDA commissioner, Sanofi's efforts t...

Pharma's TV blitz, biotech's IPO trickle, and the M&A future of Intercept Pharmaceuticals

Feb 18, 2016 - 39:23

Fierce editors discuss the rise of TV ads for specialty drugs, signs of life in the biotech IPO scene, an...

Pharma's day on the Hill, biotech's paucity of M&A, and the gathering storm of biosimilars

Feb 11, 2016 - 40:30

Fierce editors discuss a bizarre congressional hearing, how biotech's slump affects the buyout climate, a...

Gilead's wide-open future, biotech's long winter, and Sanofi's ongoing makeover

Feb 4, 2016 - 36:41

Fierce editors discuss the future of Gilead Sciences, biotech's continued slump on Wall Street, and the l...